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Learning objectives
After reading this article you should:
C know the four subtypes of opioid receptor and understand
which receptor clinical drugs target




David G Lambertwhich opioid receptors work
C understand the main physiological effects from activation of the
different subtypes of opioid receptor
C appreciate that there is interplay between the actions of the
different subtypes of receptor and hence the value of drugs
which target multiple receptor subtypes.Abstract
The opioid system comprises four receptor subtypes: m (MOP), k (KOP),
d (DOP), now called the ‘classical’ opioid receptors, and the ‘non classical’
nociceptin/orphanin FQ peptide (N/OFQ) receptor (NOP). Selective endog-
enous peptides, cleaved from larger precursor proteins, have been iden-
tified for all subtypes. Both classical and non-classical opioid receptors
couple to inhibitory, pertussis toxin-sensitive G-proteins. Opioid receptors
activate the same major intracellular pathways, which include: closing of
voltage-sensitive calcium channels; opening of potassium channels and
subsequent cellular hyperpolarization; and inhibition of cyclic adenosine
monophosphate (cAMP) production through inhibition of the enzyme
adenylate cyclase. All current, clinically used opioids work through activa-
tion of the MOP receptor. In an experimental setting, co-administration of
MOP and DOP agonists has been shown to have a synergistic analgesic
action. Administration of DOP-receptor antagonists has also been
shown to reduce tolerance, physical dependence and other side effects
of MOP-receptor agonists, without detriment to their analgesic action.
In animal models NOP agonists are analgesic when administered spinally
and have a pronociceptive/anti-analgesic (or anti-opioid) effect supraspi-
nally. NOP knockout mice show a partial loss of tolerance to morphine
and there is an up-regulation of N/OFQ production in chronic morphine
tolerant mice. Analgesic tolerance that develops from repeated exposure
to morphine is markedly attenuated in NOP knockout mice. The develop-
ment of ligands with mixed action at MOP, DOP and NOP receptors offer
new opportunities for opioid pharmacology.
Keywords G-protein-coupled receptor; MOP/DOP opioid receptor ac-
tions; NOP-receptor antagonist
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Opium and its derivatives have been used for centuries for me-
dicinal and recreational purposes. Opiates refer to the non-
peptide synthetic morphine-like drugs whilst the term opioid is
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ANAESTHESIA AND INTENSIVE CARE MEDICINE 14:11 505morphine-like actions. Opioids can be loosely divided into four
groups:
 naturally occurring endogenously produced opioid pep-
tides (e.g. dynorphin and met-enkephalin)
 opium alkaloids such as morphine purified from the poppy
Papaver somniferum
 semi-synthetic opioids (modifications to the natural
morphine structure) such as diacetylmorphine (heroin)
 synthetic derivatives with structure unrelated to morphine,
which include the phenylpiperidine series (e.g. pethidine
and fentanyl), methadone series (e.g. methadone and
dextropropoxyphene), benzomorphan series (e.g. pentaz-
ocine), and semi-synthetic thebaine derivatives (e.g. etor-
phine and buprenorphine).
Snyder and colleagues in 1973 published data showing specific
binding of opioids, providing the first evidence of distinct receptors
for these drugs. Multiple opioid receptor types were evident from
initial studies, which showed: differences in opioid potency; selec-
tive antagonism; and stereospecificity of opiate actions. Opioid-
receptor subtypes were defined from multiple studies character-
izing drug action at distinct anatomical locations and through
pharmacological profiles of opioids. ‘Classical’ opioid receptor
definition is based in part on a sensitivity to naloxone and subtypes
m (MOP), k (KOP) and d (DOP) exist. Current International Union of
Basic and Clinical Pharmacology (IUPHAR) nomenclature is
included in parenthesis and will be used for the remainder of this
article. Low-stringency hybridization screening using opioid re-
ceptor probes led to the discovery of a fourth ‘opioid-like receptor’
initially named LC132 (rat), MOR-3 (mouse) and ORL1 (human).
Following thedeorphanizingof the receptor and the identificationof
an endogenous ligand, nociceptin/orphanin FQ (N/OFQ), the re-
ceptor was classified as a ‘non-opioid’ branch of the opioid receptor
family, owing to a lack of sensitivity to naloxone whilst sharing
significant sequence homology with the classical opioid receptors.
The current nomenclature for this fourth opioid receptor subtype is
nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP).
All receptors are G-protein coupled and share the same gen-
eral structure: seven linked transmembrane-spanning domains,
an extracellular N-terminus and intracellular C-terminal tail.
Based on alignment of their amino acid sequences, all four
subtypes have an overall homology of about 60%; however, this
increases to more than 80% in the second, third and seventh
transmembrane domains. 2013 Elsevier Ltd. All rights reserved.
PHARMACOLOGYIsoforms of all opioid receptors have been suggested based
largely on pharmacological grounds, which sees the differential
effect of a drug in vivo when compared to in vitro responses or
incomplete tolerance profiles seen when alternating drugs acting
at the same receptor. There is no evidence for multiple genes
encoding opioid-receptor subtypes; opioids are encoded by single
genes which when removed, as in knock-out animals, results in
all those responses associated with the respective receptor
becoming absent. The putative isoforms of receptors reported are
accounted for in part by the alternative splicing of a single gene
resulting in alternative receptor protein structures and therefore
pharmacology, for the MOP receptor 15 splice variants have been
reported with some distinct regional distribution within the CNS.
The exact nature of the pharmacologically described subtypes
remains the subject of debate.
Endogenous opioid peptides
Hughes and Kosterlitz isolated the first endogenous opiates: two
peptides (met-enkephalin and leu-enkephalin) that competed
with morphine-like drugs for binding to receptors in the brain.
Subsequent studies identified further endogenous opioids to
include dynorphin A, dynorphin B, b-endorphin, endomorphin- 1
and -2, and N/OFQ (Table 1).1 Met- and leu-enkephalin showed
preferential binding to DOP receptors, whilst dynorphin A and B
favoured binding to KOP receptors, N/OFQ for NOP and endo-
morphin- 1 and -2 for MOP. b-endorphin has activity at all three
classical subtypes but shows some preference for MOP receptors.
Opioid peptides are cleaved from larger precursors: b-endorphin
from preproopiomelancortin; met- and leu-enkephalin from
preproenkephalin; N/OFQ from prepronociceptin; and dynorphin
A and B from preprodynorphin. The precursor(s) for endo-
morphin 1 and 2 are yet to be identified. The precursors containCharacteristics of the more common opioid peptides.
















Standard single amino acid code is used. Note that endorphins, enkephalins
and dynorphins share a common Tyr-Gly-Gly-Phe (YGGF) motif which enables
binding to classical opioid receptors (modified from1)
Table 1
ANAESTHESIA AND INTENSIVE CARE MEDICINE 14:11 506other bioactive fragments within their sequences, and in the case
of preproenkephalin, multiple copies of their respective peptides
(Table 1).2
Intracellular effectors
The four subtypes of opioid receptor couple to inhibitory,
pertussis toxin sensitive G-proteins (e.g. Gi/o). Both recombinant
and endogenously expressed opioid receptors activate the same
major intracellular pathways, which include: closing of (pre-
dominantly) N and P/Q-type voltage-sensitive calcium channels;
opening of potassium channels and subsequent cellular hyper-
polarization; and inhibition of cyclic adenosine monophosphate
(cAMP) production through the inhibition of the enzyme ade-
nylyl cyclase.2,3
G-protein-coupled receptors (GPCRs) couple to heterotrimeric
G-proteins, which are formed from three distinct subunits: a, b,
and g. There are numerous gene products encoding for the
different subunits. GPCR activation, for example MOP with
morphine, induces a conformational change in the receptor,
which allows coupling to respective G-protein subtype(s), this
will be a G-protein possessing a Gi/o a-subunit. In their resting
form G-proteins reside in a heterotrimeric complex (abg), with
guanine diphosphate (GDP) in association with the a-subunit. G-
protein association with its cognate receptor, upon ligand bind-
ing, leads to dissociation of GDP from the a subunit and binding
of guanosine triphosphate (GTP) followed by the dissociation of
a-GTP from the bg complex. Both a-GTP and bg are able to affect
different intracellular pathways through activation or inhibition
of enzymes and ion channels. G-protein GTPase activity, which
converts GTP into GDP, leads to cessation of signalling and
reforming of the a-GDP subunit with bg (Figure 1).
N/P-type voltage-sensitive calcium channels (VSCCs) are
located at synaptic terminals and play a major role in transmitter
release and therefore synaptic transmission. Some G-protein-
coupled receptors, including opioid receptors, negatively regulate
VSCC, such that their activation inhibits calcium influx, pre-
venting neurotransmitter release. Channel inhibition results from
a positive shift in the voltage dependence of the channel coupled
to a slowing of activation; the inhibition can be relieved by a
strong depolarization. Classical opioid receptors have been
shown to inhibit N-, P/Q-, L- and T-type calcium channels.
However because of their location at presynaptic terminals, N-
and P/Q-type channel modulation is thought to be of most
importance. N-type and P/Q-types calcium currents are most
sensitive to inhibition by N/OFQ. VSCC inhibition by opioids has
been demonstrated in a variety of preparations, including the
locus coeruleus, periaqueductal grey neurons and trigeminal
ganglion neurons. Overall the effect of opioids on VSCCs leads to
reduced transmitter release.3
G-protein inwardly rectifying potassium (GIRK) channels are
activated by opioid receptors. GIRK channel opening is through an
interaction with Gbg subunits released from Gi/o G-proteins and
leads to membrane hyperpolarization through an efflux of potas-
sium ions. The net effect is reduced neuronal excitability and,
through opioid receptor location on nociceptive afferents, a
concomitant reduction in nociceptive transmission. N/OFQ-
mediated activation of GIRK channels has also been demonstrated
at many central sites, including spinal cord, locus coeruleus, peri-
aqueductal grey and hypothalamus.4,5 2013 Elsevier Ltd. All rights reserved.






























Figure 1 The receptor (R) and heterotrimeric G-protein (abg) are depicted in (1). When ligand (black circle) binds (2) GDP is exchanged for GTP and the
system is activated such that a and bg dimer dissociate (3) to interact with effectors, Ca2þ channels ( close), Kþ channels (þ open) and adenylate
cyclase ( inhibit) which indirectly modulates Ih ( close). The system is turned off when the intrinsic GTPase activity of the alpha-subunit converts GTP
back to GDP (4).
PHARMACOLOGYRegulation of cAMP also plays a role in how opioid
receptors modulate the firing of nociceptive afferents. The
hyperpolarization-activated current, Ih, is an important modu-
lator of action potential firing in excitable cells and represents an
inward current activated by hyperpolarization of the resting
membrane potential. It is believed that part of the action of pro-
inflammatory mediators is through a capacity to increase the
frequency of action potentials generated from a given inward
current, and modulation of Ih is involved in this. Ih is regulated
by cAMP and increases in cAMP enhance Ih currents, reducing
refractory times, intensifying the firing of nociceptive afferents.
Opioid receptors do not act directly on the Ih channel, but
modulate it indirectly through a reduction in cAMP. In this way
the opioid receptor mediated inhibition of Ih, and reduction of
excitability in primary in afferent nerves, would only be relevant
in the presence of agents which lead to an increase in cAMP
formation.6
Types of opioid receptor
MOP receptors: the clinically used opioids work through acti-
vation of the MOP receptor. Respiratory depression accompanies
analgesic doses of morphine and related compounds. This action
is mediated by MOP receptors located within the respiratoryANAESTHESIA AND INTENSIVE CARE MEDICINE 14:11 507centres of the medulla, decreasing the sensitivity of chemore-
ceptors to carbon dioxide. Whilst this action is one of the major
side effects of opioid drugs, tolerance to its action does build.
Nausea and vomiting is prevalent in patients given morphine,
and is caused by stimulation of the chemoreceptor-trigger zone of
the medulla. Again, tolerance to this action does develop. Opi-
oids cause constipation through reduction of gastrointestinal-
tract motility. Not only is this effect unpleasant, it can also
affect the absorption of other drugs. This action is mediated via
inhibition of nerves in the myenteric plexus that cause visceral
smooth muscle contraction of the gut.
As many of the unwanted side effects of opioid drugs are
caused by activation of peripherally located opioid receptors,
there has been interest in the use of peripherally acting opioid-
receptor antagonists, unable to pass the bloodebrain barrier,
for treating these side effects. Methylnaltrexone, a peripherally
acting opioid-receptor antagonist was evaluated regarding the
incidence of postoperative nausea and vomiting. It was
concluded that this agent did not prevent or significantly reduce
the incidence/severity of postoperative nausea and vomiting.
However, methylnaltrexone given subcutaneously in patients
with opioid-induced constipation (no bowel movements for 48
hours despite the use of laxatives and stool softeners) caused 2013 Elsevier Ltd. All rights reserved.
PHARMACOLOGYlaxation within 4 hours. Alvimopan has been shown to have
gastrointestinal-selective opioid-receptor antagonist activity. It
improved postoperative recovery of bowel function and short-
ened the duration of hospital stay without compromising opioid-
mediated analgesia.7,8
DOP receptors: were the first opioid receptors to be cloned from
NG-108 (a mouse neuroblastoma hybridoma cell line) cells in
1992. Their distribution throughout the CNS is more restricted
relative to the other opioid receptors. The highest DOP receptor
densities can be found in the olfactory bulb, neocortex, caudate
putamen and nucleus accumbens, and to a lesser degree the
thalamus, hypothalamus and brainstem. DOP receptors are
located presynaptically on primary afferents where they inhibit
the release of neurotransmitters. Through both spinal and
supraspinal sites the receptor is involved in the antinociceptive/
analgesic actions of some opioids.
DOP receptors are located in bulbospinal neurons and func-
tionally identified respiratory neurons of the ventral respiratory
group. The receptor is located presynaptically and therefore
modulates transmitter release from these neurons. DOP agonists
have a role in central respiratory pattern generation but have a
lesser role in respiratory rhythm generation. However, it has
been demonstrated that DOP-respiratory depression is absent in
MOP-deficient species. Also of note is a reduction in DOP-
receptor mediated analgesia in MOP knockout species. There-
fore, both the analgesic properties and respiratory effects of DOP
receptor activation may, in part, be dependent on the presence of
functionally active MOP receptors (i.e. MOP/DOP-receptor
cooperativity or synergy takes place). Since DOP-mediated
intracellular signalling was unaffected in mice deficient of the
MOP receptor, it is likely that the MOP/DOP interaction occurs
through distinct locations on neuronal networks.
Currently, there are no clinical drugs in use that work via
activation of the DOP receptor. One major area of interest
regarding DOP-receptor activation is an antidepressant-like ef-
fect. Indeed, DOP-deficient mice display a depressant-like
phenotype and anxiogenic-like responses. Enkephalinase in-
hibitors have also been shown to produce antidepressant-like
actions in animal paradigms, as have DOP receptor agonists.
Current interest lies in the development of drugs with agonist
activity at both DOP and MOP, and drugs that have agonist ac-
tivity for MOP and antagonist actions at DOP. The rationale for
this approach comes from studies in which co-administration of
MOP and DOP agonists revealed a synergistic analgesic action
such that sub-antinociceptive doses of leu-enkephalin potentiate
the analgesia elicited by morphine. The administration of DOP
receptor antagonists reduces tolerance, physical dependence and
other side effects of MOP-receptor agonists without detriment to
their analgesic action. Development of tolerance and dependence
to morphine following chronic dosing was blocked by antisense
oligonucleotides directed against the DOP receptor. In addition,
wild-type mice were shown to lose their analgesic response to
daily morphine dosing after 5 days, whilst DOP-receptor
knockout mice failed to develop tolerance after 8 days’
administration.9
Bivalent ligands are single drug molecules with two pharma-
cophoric regions (motifs responsible for a drugs action).
Combining the pharmacophores of oxymorphone and naltrindoleANAESTHESIA AND INTENSIVE CARE MEDICINE 14:11 508in one drug, by way of a 21-atom linker, lead to MDAN-21, a
bivalent ligand which when compared to morphine had
improved antinociception and a reduction in the development of
tolerance.10 Bi-functional drugs, like bivalent drugs, also interact
with multiple receptor targets; however they are chemically
different in having only one pharmacophoric region capable of
achieving multiple receptor interactions. Bi-functionals able to
produce both MOP agonism and DOP antagonism have also been
reported and include UFP-505 which utilizes a DMT-tic phar-
macophore to achieve its mixed opioid pharmacology.10
KOP receptors: have been implicated in a number of functions,
including nociception, diuresis and feeding. Activation of the
KOP receptor has been shown to produce actions distinct from
those elicited by stimulation of the MOP receptor, importantly
sedation without marked effects on heart rate. Further, KOP re-
ceptors do not cause respiratory depression and therefore have
been of great interest due to their potentially safer side-effect
profile. Two synthetic KOP receptor agonists, spiradoline (U-
62,066E) and enadoline (CI-977) have undergone clinical trials
for their analgesic actions.11,12 Spiradoline produced analgesia in
animal models; however, clinical data showed that spiradoline
produced adverse effects such as diuresis, sedation and
dysphoria at doses lower than that needed for its analgesic ef-
fects. Enadoline had a similar side-effect profile of sedation,
confusion, dizziness along with increased urinary output and
feelings of depersonalization. The side effects elicited by these
and other KOP receptor agonists limit their effective clinical
usage.
Whilst the use of KOP ligands for the treatment of pain is
currently limited there appear to be a number of potential
alternative uses, including the treatment of alcohol dependence.
Moreover, a role for dynorphin and the KOP receptor in epi-
leptogenesis and epilepsy has also been recently demonstrated.
NOP receptors: the observation that NOP regulates similar
transduction mechanisms to those of classical opioids, the high
sequence homology of the endogenous KOP receptor peptide
dynorphin A to N/OFQ and abundant overlap of NOP receptor
distribution with classical opioid receptors suggests that NOP
and N/OFQ are related to the opioid family.
N/OFQhas been shown to have both pre- and postsynaptic sites
of action. The superficial dorsal horn expresses high levels of NOP-
receptor and N/OFQ peptide mRNA. Studies mapping the binding
of N/OFQ and measuring mRNA for N/OFQ indicate similar dis-
tribution.N/OFQ and its receptor arewidely expressed throughout
both the central and the peripheral nervous system and show
broad overlap with classical endogenous opioids and receptors.13
Application of N/OFQ has been shown to cause hyperalgesia,
allodynia and analgesia.14 However, the route of administration
and nociceptive paradigm under investigation determine the
observed response. Nevertheless, most studies conclude that
intrathecally administered N/OFQ causes analgesia.
There has been much controversy over the supraspinal effects
of N/OFQ. Original studies reported that intracerebroventricular
administration caused hyperalgesia compared with vehicle
treated groups.5 It has since been shown that there is no differ-
ence between the pain threshold of intracerebroventricular N/
OFQ-treated and vehicle-treated animals. Therefore, it is 2013 Elsevier Ltd. All rights reserved.
PHARMACOLOGYassumed that N/OFQ does not cause hyperalgesia but reverses
the opioid-mediated stress-induced analgesia caused by the
experimental procedure.
The anti-opioid role ofN/OFQhas subsequently beenvalidated,
and N/OFQ is known to counteract analgesia elicited through the
endogenous opioid system and analgesia from exogenously
applied morphine. The overall effect of a systemic dose of N/OFQ
would be dependent on both its antinociceptive action at spinal
sites, and its supraspinal pro-nociceptive/anti-opioid action. The
relative contribution at both these sites, coupledwith the degree of
resting supraspinal endogenous-opioid tone, would influence the
overall outcome of systemic N/OFQ.
Mixed opioids with activity at NOP are also of pharmacolog-
ical interest. Indeed buprenorphine, which has agonist activity at
both MOP and NOP, is one such drug in clinical use. ‘In both
animals and humans a hallmark of the antinociceptive action of
buprenorphine is the production of a ceiling effect or a bell
shaped curve’.15,16 The ceiling effect, which is seen in man, may
be caused simply through buprenorphine partial agonist activity.
However subsequent activation of NOP receptor mediated anti-
opioid activity may set the ceiling response of buprenorphine
and is certainly responsible for the falling phase of buprenor-
phine’s bell shaped curve. It may be also suggested that the
supraspinal actions of NOP not only compromise the MOP
mediated actions of buprenorphine but also override the possible
spinal NOP mediated antinociception of buprenorphine.
The chronic use ofMOP-receptor analgesics, such asmorphine,
results in tolerance and a reduction in analgesia from a fixed dose.
The anti-analgesic action of the NOPeN/OFQ system may play a
key role in development of this type of tolerance. Indeed, NOP
knockout mice show a partial loss of tolerance to morphine, and
there is up-regulation of N/OFQ production in chronic morphine-
tolerant mice.17 Analgesic tolerance that develops from repeated
exposure to morphine is markedly attenuated in NOP knockout
mice. Acute morphine analgesia is unaffected in NOP knockout
species. This action has also been confirmed using potent selective
NOP antagonists, which additionally attenuate morphine toler-
ance.18 These findings suggest the NOPeN/OFQ system may
contribute to the neuroplasticity that accompanies tolerance from
chronic morphine exposure.17 NOP blockade may prove useful in
reducing tolerance to opioids and/or reducing the dose required to
provide analgesia.17With this ismind themerits of a drugwith that
behaves as an NOP antagonist and MOP agonist are clear, indeed
one particular experimental molecule SR-14148 has already been
presented in the literature.19 A
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